Article Text

Download PDFPDF
Remission of type 2 diabetes is achievable in primary care with intensive lifestyle intervention
  1. Sophia Zoungas1,
  2. Priya Sumithran2
  1. 1School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia
  2. 2School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia
  1. Correspondence to Professor Sophia Zoungas, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; sophia.zoungas{at}monash.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: Hocking SL et al. Intensive Lifestyle Intervention for Remission of Early Type 2 Diabetes in Primary Care in Australia: DiRECT-Aus. Diabetes Care 2024;47:66–70.

Implications for practice and research

  • Intensive lifestyle intervention in primary care can safely achieve type 2 diabetes (T2D) remission at 12 months in around half of selected participants with short-duration, well-controlled T2D.

  • Research on the effectiveness and acceptability of strategies to improve durability of remission is needed.

Context

Although previously thought to be inevitably progressive, evidence is growing that type 2 diabetes (T2D) can be brought into remission with weight loss.

This study by Hocking et al1 was a single-arm replication of the Diabetes Remission Clinical Trial (DiRECT) randomised controlled trial2 in an Australian setting. It confirms that with an intensive lifestyle intervention including total diet replacement (TDR), around half of adults with recently diagnosed T2D can achieve remission at 12 months.1

Methods

Adults with T2D of up to 6 years’ duration and body mass index (BMI) >27 kg/m2 were recruited from 25 primary care practices. Participants received a …

View Full Text

Footnotes

  • Competing interests Sophia Zoungas is employed by Monash University and receives funding from NHMRC, MRFF, and the Commonwealth Department of Health and Aged Care. She reports previous payment to institution (Monash University) from Amgen Australia, AstraZeneca, Eli Lilly Australia, Moderna, MSD Australia, Sanofi and Novo Nordisk for participation in advisory and educational meetings unrelated to this work.

    Priya Sumithran has coauthored manuscripts where a medical writer was provided by Novo Nordisk and Eli Lilly.

  • Provenance and peer review Commissioned; internally peer reviewed.